stockrowNephros Inc.
NEPH Healthcare Medical Instruments & Supplies
Nephros Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.8 million, up 32.7% from fiscal 2024.
- Revenue
- +18.0%
- EPS
- +66.7%
- Free cash flow
- −251.5%
Quarter to September 2026, against a year earlier
Follow NEPH
Alert me
Nephros Inc. (NEPH) EV/Sales
As of 5 November 2026, Nephros Inc. (NEPH) trades at a EV/Sales of 1.4×. Over the past ten years it has ranged from 0.5× (September 2022) to 13.4× (August 2016); the current reading is higher than 22% of that period. That is below the Medical Instruments & Supplies industry median of 2.8× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.5× | 198.42% |
| FY2024 | 0.8× | (62.39%) |
| FY2023 | 2.2× | 181.29% |
| FY2022 | 0.8× | (84.70%) |
| FY2021 | 5.1× | (38.40%) |
| FY2020 | 8.3× | 19.04% |
| FY2019 | 7.0× | 22.46% |
| FY2018 | 5.7× | (6.81%) |
| FY2017 | 6.1× | (32.31%) |
| FY2016 | 9.0× | 174.01% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 1.7× | 0.80% |
| Jun 2026 | 1.6× | 13.39% |
| Mar 2026 | 1.4× | (41.28%) |
| Dec 2025 | 2.5× | (1.68%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DXR Daxor Corporation compare | −12.5× |
| RVP Retractable Technologies, Inc. compare | −0.7× |
| BNGO Bionano Genomics, Inc. compare | 0.7× |
| POCI Precision Optics Corp. compare | 1.1× |
| HBIO Harvard Bioscience, Inc. compare | 1.2× |
| NEPH Nephros Inc. | 1.4× |
| MLSS Milestone Scientific, Inc. compare | 2.8× |
| ZTEKF Zentek Ltd. compare | 259× |
| DAVI Davion Healthcare PLC compare | — |
| Medical Instruments & Supplies industry median | 2.8× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)